mProX™ Human CLK3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1092	Magic™ Human CLK3 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

CLK3

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

SMMC-7721; SK-hep-1; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Related Diseases

Among its related pathways are Processing of Capped Intron-Containing Pre-mRNA and Translational Control

Gene ID

1198

UniProt ID

P49761

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

A dual-specificity protein kinase involved in the control of gene splicing is called CLK3 (CDC Like Kinase 3). There are four members of the CLK family: CLK1/STY, CLK2, CLK3, and CLK4. Researching disorders linked to mis-splicing occurrences in genes can benefit from focusing on CLKs. Regarding the specified accession number, the translational conflicts T132S and G133S are present in the CLK3 construct. Both of these are documented in GB BC019881. The human CLK3 gene encodes the enzyme dual specificity protein kinase (CLK3). A protein kinase of the serine/threonine type with a non-conserved N-terminal domain is encoded by the CLK3 gene. Alternative splicing produces two isoforms, phclk3 and pclk3/152, which coexist in distinct tissues. Phclk3/152 isoform is devoid of the kinase domain. The customized CLK3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Paul

I have been using the CLK3 cell line for my research, and it has consistently provided reliable results. Mar 20 2021

chat Verified Customer

chat Sharon

The specificity and reproducibility of this CLK3 cell line are impressive. I highly recommend it to fellow researchers. May 26 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Knockdown of CLK3 inhibits HCC cell proliferation, migration and invasion.

SMMC-7721 or SK-hep-1 HCC cells were transfected with either a separate shRNA targeting CLK3 or a negative control (NC). 48 hours later, the knockdown efficiency was assessed by Western blot.

Ref: Li, Hua, et al. "CLK3 is a direct target of miR-144 and contributes to aggressive progression in hepatocellular carcinoma." OncoTargets and Therapy 12 (2019): 9201.

Pubmed: 31807004

DOI: 10.2147/OTT.S224527

Research Highlights

These results indicate a possible therapeutic value for CLK3, demonstrating its critical involvement in CCA purine metabolism.
Zhou, Qingxin, et al. "Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism." Journal of Experimental Medicine 217.8 (2020): e20191779.
Pubmed: 32453420 DOI: 10.1084/jem.20191779

The most prevalent and frequently occurring kind of primary liver cancer is hepatocellular carcinoma (HCC). Numerous studies have been conducted on the underlying molecular pathways of HCC development. Nuclear dual-specificity kinase CLK3 (CDC Like Kinase 3) controls gene splicing.
Li, Hua, et al. "CLK3 is a direct target of miR-144 and contributes to aggressive progression in hepatocellular carcinoma." OncoTargets and Therapy 12 (2019): 9201.
Pubmed: 31807004 DOI: 10.2147/OTT.S224527